ライフサイエンスコーパス: case fatality rate

1 isease onset in the population, and the high case fatality rate.

2 e (LD) is a preventable pneumonia with a 30% case fatality rate.

3 rious neuroinvasive disease with up to a 10% case fatality rate.

4 in a number of human infections with a high case fatality rate.

5 d outbreaks of a SARS-like illness with high case fatality rate.

6 rates of other serious adverse events or the case fatality rate.

7 to determine trends in annual incidence and case fatality rate.

8 tions, and comorbidity, and carries a higher case fatality rate.

9 or endocardial fibroelastosis quadrupled the case fatality rate.

10 a fatal zoonotic disease with a nearly 100% case fatality rate.

11 t hospitals probably contributed to the high case-fatality rate.

12 nfirmed cases have been reported, with a 53% case-fatality rate.

13 e interval, 18.7-34.1) with no change in the case-fatality rate.

14 Disease carried a high case-fatality rate.

15 (LASV) can cause hemorrhagic fever with high case fatality rates.

16 use human viral hemorrhagic fevers with high case fatality rates.

17 us cause serious disease outbreaks with high case fatality rates.

18 injury is likely to reduce historically high case fatality rates.

19 that are known to cause infections with high case fatality rates.

20 icant public health concern and lead to high case fatality rates.

21 or hospitalization and mortality but similar case fatality rates.

22 causing outbreaks of disease with very high case fatality rates.

23 ce it continues to cause outbreaks with high case fatality rates.

24 d Sudan (SUDV) cause human disease with high case fatality rates.

25 and respiratory disease in humans with high case fatality rates.

26 rus that causes sporadic outbreaks with high case fatality rates.

27 new areas has often been accompanied by high case-fatality rates.

28 den of invasive disease with high associated case-fatality rates.

29 Age/sex/race-adjusted case-fatality rates.

30 measures were population mortality rates and case-fatality rates.

31 ties in screening for cancer and with higher case-fatality rates.

32 Results were standardised to UK case-fatality rates.

33 gnostics and management contributing to high case-fatality rates.

34 19 before doing cross-country comparisons of case-fatality rates.

35 gnostics and management contributing to high case-fatality rates.

36 fatality rate 7.0%) and 48/211 (23% deaths, case fatality rate 1.4%) met the criteria for severe mal

37 ase severity was assessed with four markers: case-fatality rate (1.3%), length of ICU stay (mean, 3.0

38 .8 cases per 100,000 persons with 56 deaths (case fatality rate, 10.7%).

39 100 000 persons per year) with 1116 deaths (case-fatality rate, 11.7%).

40 ially despite a continuous decline in 30-day case fatality rate (12.5% in 1979 to 1989; 6.7% in 2000

41 bclade D having the highest 30-day estimated case-fatality rate (19% vs 3%-14%).

42 h leukaemia showed a significantly increased case-fatality rate (2.25, 1.13-4.57; p=0.023).

43 total of 7615 cholera cases with 181 deaths (case fatality rate = 2.4%).

44 Overall case-fatality rate (30 days) was higher in patients with

45 COVID-19 diagnosis did not impact survival (case fatality rate, 34% vs 35%), though the BTKi was hel

46 atory-confirmed MERS-CoV infection, 93 died (case fatality rate, 36.5%).

47 e 3146 IPD cases and 150 IPD-related deaths (case fatality rate, 4.8%).

48 e 6.2%), of whom 27 had early-onset disease (case fatality rate 5.2%) and 26 had late-onset disease (

49 corded in 17 states, including seven deaths (case fatality rate 6%).

50 53 infants died (case fatality rate 6.2%), of whom 27 had early-onset dis

51 tted with malaria died; 163/211 (77% deaths, case fatality rate 7.0%) and 48/211 (23% deaths, case fa

52 ty rate 5.2%) and 26 had late-onset disease (case fatality rate 7.7%).

53 The EOD case fatality rate (71%) was higher than in LOD (32%) or

54 Case-fatality rate (8%) and development of sequelae (29%

55 onfirmed and 106 suspected) were identified (case fatality rate, 83 percent); 52 percent of cases wer

56 l MARV infection outbreak in history, with a case-fatality rate (90%) similar to that for Zaire ebola

57 Gastrointestinal bleeding incidence and case-fatality rates account only for age and sex.

58 Clinical outcomes studied included adjusted case fatality rates (aCFR), including the ratio of weeke

59 s independently associated with an increased case fatality rate (adjusted subdistribution hazard rati

60 52% to 2.94%), contrasting with a decreasing case fatality rate among hospitalizations (annual percen

61 We sought to estimate the case fatality rate among hospitalizations or emergency d

62 Case fatality rate among patients who received monothera

63 The incubation period and case fatality rate among patients with EVD in Sierra Leo

64 t this increase was offset by the decreasing case fatality rate among those hospitalized; both inpati

65 Case fatality rates among African children with cerebral

66 Case fatality rates among hospitalized patients diagnose

67 umonia and 42% (95% CI, 18%-59%) in reducing case fatality rates among patients with influenza, using

68 The case-fatality rate among the 9 total cases was 22%.

69 usness led to extraordinary attack rates and case-fatality rates among HIV-infected persons.

70 are risk-adjusted complication incidence and case-fatality rates among patients experiencing serious

71 Despite the high case fatality rate and large number of persons at risk o

72 There were significantly elevated case fatality rates and elevated liver transaminase leve

73 associated coronavirus (MERS-CoV) cause high case fatality rates and remain major human public health

74 ndemic threat because of its associated high case-fatality rates and capacity for human-to-human tran

75 everity was assessed by means of in-hospital case-fatality rates and compared by group as cohort stud

76 -based therapeutic care substantially reduce case-fatality rates and increase coverage rates.

77 The high case-fatality rates and potential for use as a biologica

78 ia, coverage of antimalarial drug treatment, case fatality rate, and population distribution accordin

79 easures were incidence rate, mortality rate, case fatality rate, and survival to discharge for patien

80 s in annual hospital admission rates, 28-day case fatality rates, and mean length of stay for stroke,

81 ls with calibrated parameters for infection, case fatality rates, and vaccine efficacy, basic childho

82 ERS-CoV) infection is associated with a high case-fatality rate, and the potential pandemic spread of

83 stimates, baseline GI bleeding incidence and case-fatality rates, and disutilities associated with as

84 atal encephalitis infections in humans, with case fatality rates approaching 75%.

85 the most deadly infectious diseases, with a case-fatality rate approaching 100%.

86 Case fatality rates are estimated to be in the 30% range

87 In high-burden settings, case fatality rates are reported to be between 11% and 3

88 acity, which limits the effect of treatment; case-fatality rates are 20-30% and coverage is commonly

89 re hemorrhagic fever in humans with reported case fatality rates as high as 90%.

90 avirus causes severe hemorrhagic fever, with case fatality rates as high as 90%.

91 damage, and shock culminating in death, with case fatality rates as high as 90%.

92 broadly positively associated with COVID-19 case fatality rates at the country level, the opposite i

93 ociated with devastating human disease, with case fatality rates averaging 30%.

94 Case fatality rates below 6% have now been recorded in t

95 Case fatality rate by antimicrobial regimen was calculat

96 empyema, sepsis, or respiratory disease) and case fatality rates by serotype and age group (5, 5-64,

97 We then created collective surgical case fatality rates by WHO region.

98 estimated the risk of hospital admission and case fatality rate caused by pneumonia in HIV-infected c

99 The case fatality rate (CFR) for children was 48.7%, with Eg

100 idemic areas are continuing to grow, but the case fatality rate (CFR) has steadily decreased.

101 e (CAR), with a "low severity" scenario with case fatality rates (CFR) of 0.05%-0.1%, or a "high seve

102 actors for adverse outcomes, and examined ED case fatality rates (CFR).

103 The suicide case-fatality rate (CFR)-the proportion of suicidal acts

104 11] vs 9.9% [964 of 9755]; P < .001) and the case fatality rate ([CFR] 13.7 [469 of 3429] vs 7.6 [134

105 There were 31 deaths (case fatality rate [CFR], 6.2% [95% confidence interval,

106 olera and 2641 deaths were reported (overall case-fatality rate [CFR], 3.9%), affecting all regions o

107 Case fatality rates (CFRs) during 2010-2017 were calcula

108 ith ineffective antimicrobials may result in case fatality rates (CFRs) exceeding 70%(4,5).

109 rhage, and multiorgan failure with up to 33% case fatality rates (CFRs).

110 We analyzed surveillance data and estimated case fatality rates (CFRs).

111 and symptoms at disease onset and calculated case fatality rates (CFRs).

112 nts may face increased acquisition risks and case fatality rates (CFRs).

113 ation in coronavirus disease 2019 (COVID-19) case-fatality rates (CFRs) across countries, leading to

114 l regression analyses to explore patterns in case-fatality rates (CFRs) at 30 days and 1 year and to

115 The cumulative case fatality rate consistently trended downward, reachi

116 ) and 5.6% (p < .001), respectively, whereas case fatality rate decreased by 1.4% (p < .001).

117 However, case fatality rates decreased during the same study peri

118 ong patients diagnosed with 1 condition, the case-fatality rate decreased in a stepwise fashion acros

119 ngitis, a life-threating disease with a high case fatality rate despite treatment with antibiotics.

120 The case fatality rate did not change significantly: it was

121 Case fatality rate did not substantially differ between

122 The case-fatality rate differed significantly between subcla

123 Morbidity and case-fatality rate due to PM remain substantial.

124 ease in humans and other primates, with high case fatality rates during human outbreaks.

125 oronavirus 2 (SARS-CoV-2) prevalence and the case-fatality rate during hospital admission.

126 in was found to be effective in reducing the case-fatality rate, especially among moderately ill pati

127 Based on our model, case fatality rate estimates by subregion ranged from 0.

128 bling rates with a roughly 2 week delay, and case fatality rates exhibit a positive feedback pattern.

129 ts selected by using perfusion CT, including case-fatality rate, favorable outcome (modified Rankin S

130 ,000 population (p < .001), whereas hospital case fatality rate fell from 45.8% +/- 0.17% to 37.8% +/

131 ospital precludes adequate assessment of why case-fatality rates fell.

132 edicted 1-year age- and comorbidity-adjusted case fatality rate for a 65-year-old patient decreased i

133 the accidental nature of the ingestions, the case fatality rate for pediatric patients is significant

134 The case fatality rate for residents was 33.7% (34 of 101).

135 The case fatality rate for S.

136 We then calculated the size-specific cancer case fatality rate for two time periods: a baseline peri

137 a virus causes hemorrhagic fever with a high case fatality rate for which there is no approved therap

138 We examined trends in case fatality rates for all-cause clinical pneumonia and

139 We validated our model against known case fatality rates for caesarean delivery.

140 Disparities in case fatality rates for heart disease among ethnic group

141 In this study, age-adjusted case fatality rates for hospitalized white and black pat

142 Reductions in short-term case fatality rates for myocardial infarction appear to

143 Lower socioeconomic groups had higher case fatality rates for stroke and ischaemic heart disea

144 al admission rates and greater reductions in case fatality rates for stroke and ischaemic heart disea

145 recent advances have not led to declines in case fatality rates for women.

146 the regional frequency of diagnoses and the case-fatality rate for chronic conditions.

147 The case-fatality rate for COVID-19 varies markedly by age,

148 The case-fatality rate for first stroke is also higher in Am

149 The overall in-hospital case-fatality rate for patients who developed cardiogeni

150 ulation for relevant age and sex groups) and case-fatality rate for primary acute myocardial infarcti

151 Here, using a global dataset of >4,000 case-fatality rates for 65 infectious diseases (caused b

152 ds (2001-2011) in the incidence and hospital case-fatality rates for patients who developed cardiogen

153 The case-fatality rates for septic shock, STSS, and NF were

154 There is a 30% higher case fatality rate from cancer in psychiatric patients e

155 Case fatality rate from typhoid-associated intestinal pe

156 ough the disease is treatable, reported RMSF case fatality rates from this region are high (7%) compa

157 The overall age-adjusted 30-day case-fatality rate from first stroke was 18%, with a 1-y

158 ratory illness and is associated with a high case fatality rate; however, the pathogenesis of severe

159 However, case fatality rate in 2012 remained high for children wi

160 ons with this isolate led to a 100% apparent case fatality rate in birds.

161 us cardiopulmonary syndrome (HCPS) has a 35% case fatality rate in Chile and no specific treatment.

162 There was a significantly higher case fatality rate in minorities compared with whites, w

163 the highest bacterial meningitis attack and case fatality rate in the world.

164 Crude 30-day, 1-year, and 5-year case fatality rates in 1960 to 1969 and 1990 to 1999 wer

165 Case fatality rates in severe falciparum malaria depend

166 Case fatality rates in west Africa were initially greate

167 The case-fatality rate in favipiravir-treated patients was l

168 The case-fatality rate in HEU infants (29% [74/253]) was int

169 The all-cause case-fatality rate in patients with cancer after SARS-Co

170 cation rates or failure to rescue rates (ie, case-fatality rates in patients with a complication).

171 remic infections, including 7-day and 30-day case-fatality rates, in Finland during 2004-2014 and lin

172 NTS can be difficult to treat and have high case-fatality rates, in part due to emergence of strains

173 ese deaths can be estimated by 4 approaches: case-fatality rate, infection-related mortality, and exc

174 f age (49.9% male), and we estimate that the case fatality rate is 70.8% (95% confidence interval [CI

175 enomenon as well as the contributors to high case-fatality rate is a growing public health concern to

176 ly on supportive care, which, given the high case-fatality rate, is not highly effective.

177 ywhere near the current confirmed H5N1 human case-fatality rate, it could endanger the lives of hundr

178 EVD has a high case-fatality rate; it is characterized by fever, gastro

179 Inpatient trauma case fatality rates may provide an incomplete assessment

180 n-Hispanic White populations, but not higher case-fatality rates (mostly reported as in-hospital mort

181 re fewer than 600 in number, with an overall case fatality rate of >50%.

182 xis did not result in death, with an average case fatality rate of 0.3%.

183 a downward trend in mortality, with a 14-day case fatality rate of 1.0% or less in most areas.

184 The case fatality rate of 1182 patients with laboratory-conf

185 th hemorrhagic manifestations and an initial case fatality rate of 12 to 30% was reported.

186 um infection is cerebral malaria (CM) with a case fatality rate of 15-25% in African children despite

187 firmed in Jiangsu and Anhui provinces with a case fatality rate of 16.1%.

188 edicted risk of poor outcome (25%-50% risk): Case Fatality Rate of 21% in the placebo group and 52% i

189 evaluated, 21 died, representing an overall case fatality rate of 30%.

190 d by a coronavirus, is highly lethal, with a case fatality rate of 35 to 40%.

191 ted in 1,791 cases of MERS and 640 deaths (a case fatality rate of 36%).

192 Among these, there were 44 deaths, for a case fatality rate of 5.1%.

193 6903 of whom died, and calculated an overall case fatality rate of 6.6% (95% CI 6.4-6.7).

194 Penicillin was associated with a case fatality rate of 75%.

195 humans and nonhuman primates, with a median case fatality rate of 78.4%.

196 The outbreak had a case fatality rate of 80%.

197 , and some hemorrhagic manifestations with a case fatality rate of about 2 to 15%.

198 96 confirmed cases of SARS and 774 deaths (a case fatality rate of approximately 10%).

199 vel coronavirus (named SARS-CoV-2) and has a case fatality rate of approximately 2%, started in Wuhan

200 assa fever, a viral hemorrhagic fever with a case fatality rate of approximately 30% in Africa.

201 ike symptoms and multi-organ failure, with a case fatality rate of approximately 36%.

202 respiratory syndrome (MERS), and an initial case fatality rate of more than 40%.

203 no deaths in the exposed group, the overall case fatality rate of the cardiac-NL fetuses in the unex

204 otein that appear to be associated with high case fatality rate of these coronaviruses as well as the

205 ver in humans and non-human primates, with a case fatality rate of up to 88% in human outbreaks.

206 eaths out of 2 319 066 confirmed cases, at a Case Fatality Rate of ~6.8%.

207 , or septicemic (5%) plague, with associated case fatality rates of 17%, 27%, and 38%, respectively.

208 Recently, case fatality rates of acute pancreatitis have stabilize

209 noglycosides were associated with the lowest case fatality rates of all antimicrobials used for treat

210 signated hantavirus pulmonary syndrome, with case fatality rates of around 40%.

211 In the as-treated analysis, case fatality rates of bleeding leading to hospitalizati

212 Case fatality rates of filovirus disease outbreaks are a

213 is the most lethal Ebola virus species, with case fatality rates of up to 90%.

214 ate from first stroke was 18%, with a 1-year case-fatality rate of 32%.

215 Previous studies describe a case-fatality rate of 5%-15% and up to 20% of survivors

216 reatic ductal adenocarcinoma has the highest case-fatality rate of any solid tumour, highlights the u

217 It has been suggested that the true case-fatality rate of human H5N1 influenza infection is

218 ardial infarction had two to three times the case-fatality rate of patients in whom acute myocardial

219 s caused outbreaks in human populations with case-fatality rates of approximately 36%.

220 mporary trends in the incidence and hospital case-fatality rates of cardiogenic shock in patients hos

221 Case-fatality rates of the African species in man are as

222 (MARV) is a filovirus with documented human case-fatality rates of up to 90%.

223 nnual suspected meningitis cases and deaths (case fatality rate) progressively declined from 2534 to

224 rus disease in humans is highly lethal, with case fatality rates ranging from 25 to 90%.

225 ons and encephalitis in Southeast Asia, with case fatality rates ranging from 40% to more than 90%.

226 a severe hemorrhagic fever in humans with a case-fatality rate ranging from 25 to 36%.

227 in humans and nonhuman primates (NHPs), with case-fatality rates ranging from 23% to 90%.

228 eported worldwide and associated with a high case fatality rate, reinforcing the need for strongly co

229 African American women also have case fatality rates related to preeclampsia 3 times high

230 ctions that are mild or subclinical, and the case-fatality rate remain largely unanswered.

231 a (38.09%), and North America (29.64%) while case fatality rates remained higher in the European temp

232 evere malaria in Malaysian Borneo, with high case-fatality rates reported.

233 Corresponding BCG versus control case-fatality rate RRs were 0.58 (95% CI, .35-.94), 0.56

234 The case fatality rate significantly decreased between 2001

235 ribavirin and corticosteroid therapy on the case-fatality rate, stratified by SSI.

236 espiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availabilit

237 rge tumors, the decline in the size-specific case fatality rate suggests that improved treatment was

238 ently, many cases were reported with a lower case fatality rate than initial cases.

239 espread in South Africa and carries a higher case fatality rate than previously appreciated.

240 tients under the age of 21 years had a lower case fatality rate than those over the age of 45 years (

241 0,000 EBOV copies per milliliter had a lower case fatality rate than those with 10 million EBOV copie

242 mic heart disease, but greater reductions in case fatality rates than higher socioeconomic groups.

243 ore at risk of substantially higher COVID-19 case fatality rates than those currently seen in high-in

244 (EBOV), causes lethal hemorrhagic fever with case fatality rates that have exceeded 50% in some outbr

245 (HCPS) is a rodent-borne disease with a high case-fatality rate that is caused by several New World h

246 The high case fatality rate, the ability to bind to receptors in

247 oincident with their geographical origin and case-fatality rate; the latter implicated putative prote

248 Other than the case fatality rate, there were no clear differences in t

249 auses a severe hemorrhagic disease with high case fatality rates; there are no approved vaccines or t

250 provements in hospital care may have reduced case fatality rates though a lack of sufficient data on

251 originated epidemics of acute disease with a case fatality rate thought to vary by age and pregnancy

252 es and social mobility on doubling rates and case fatality rates through a time-varying regression mo

253 ogress to primary septicaemia have a similar case fatality rate to category BSL 3 and 4 pathogens, su

254 ng that convalescent transfusions reduce the case-fatality rate to 12.5% (range, 7.5%-17.5%), we proj

255 emorrhagic fever in East Asia, with reported case fatality rates up to 30%.

256 re hemorrhagic fever in primates, with human case fatality rates up to 90%.

257 holderia pseudomallei and is associated with case-fatality rates up to 40%.

258 he start of the epidemic, the rolling 14-day case fatality rate was 1.0% and remained at or below thi

259 with an aminoglycoside (n = 407 [53%]), the case fatality rate was 13%.

260 The case fatality rate was 20% overall.

261 The case fatality rate was 29.1% (122/419).

262 The overall case fatality rate was 29.2%, which declined from 35.4%

263 Case fatality rate was 3.1%.

264 AML patients were identified; the induction case fatality rate was 3.7%.

265 The observed 60-day case fatality rate was 30.6%.

266 t a median follow-up of 16 days, the overall case fatality rate was 33%, though 25% remain admitted.

267 Case fatality rate was 37% (55/150).

268 The overall case fatality rate was 57%.

269 Pneumococcal meningitis case fatality rate was 6-fold higher than that of mening

270 od was estimated to be 6 to 12 days, and the case fatality rate was 74%.

271 The Hib-associated case fatality rate was 9.4% (10/106 cases).

272 In this outbreak the case fatality rate was about 67%.

273 able analyses indicated that the decrease in case fatality rate was consistent across most subgroups.

274 sed compared to immunocompetent persons; the case fatality rate was elevated in both younger (odds ra

275 The case fatality rate was estimated at 74.4% (95% CI, 68.3,

276 ates in males exceeded those in females, but case fatality rate was greater in females.

277 ars; interquartile range, 18-40), the 2-year case fatality rate was high (500 deaths, 16.9%).

278 The case fatality rate was highest for C. difficile (40%), r

279 months (interquartile range, 12-72) and the case fatality rate was highest in those unconscious (44.

280 The in-hospital case fatality rate was low (0.15%) and relapses were rar

281 The case-fatality rate was 0.04%.

282 The overall crude case-fatality rate was 16% (54 of 336) among treated pat

283 diagnosed with 0, 1, 2, and 3 conditions the case-fatality rate was 16, 45, 93, and 154 per 1000, res

284 The in-hospital case-fatality rate was 17% (247/1479).

285 The overall crude case-fatality rate was 19% (28 of 148) among patients wh

286 The overall case-fatality rate was 40%.

287 The case-fatality rate was 90%.

288 The case-fatality rate was 91%; 2 cases survived.

289 The overall case-fatality rate was higher among patients with XDR P.

290 Our observed case-fatality rate was lower than has been reported from

291 l-to-diagnosis conversion rates and COVID-19 case-fatality rates, we also estimated the survival incr

292 Case fatality rates were 1.1% (12/1,098) for MAM and 1.2

293 Case fatality rates were between 0.25% and 0.33% among h

294 HF case fatality rates were examined.

295 fects of ribavirin and corticosteroid on the case-fatality rate were studied by univariate and multiv

296 Sepsis case-fatality rates were 13% greater in the winter compa

297 agnosed with 3 conditions, the corresponding case-fatality rates were 168 and 137 per 1000 (relative

298 Case-fatality rates were not significantly different acr

299 lated heart block was associated with a 7.8% case fatality rate, whereas the concomitant presence of

300 l occurring throughout Saudi Arabia at a 38% case fatality rate, with the potential for worldwide spr